Search

… des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 Cet accès … à soutenir une évaluation et une approbation accélérées ProQR estime que l'Union européenne représentera un marché … et CAMBRIDGE, Mass., 29 juill. 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq : PRQR), une entreprise dédiée …

… ProQR Announces Clearance of IND to Start Clinical Trial of … Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Investigational New Drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a Phase 1/2 trial …

… ProQR to Present Top-Line Results from the Phase 1/2 Study of … Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … from the FDA as well as PRIME access by the EMA. About ProQR ProQR Therapeutics is dedicated to changing lives …

… ProQR Therapeutics and Yarrow Biotechnology, an RTW … sectors, and ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the … newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide technology (ASO) to develop …

… ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific … Editing Technology Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him … chaired by Gerard Platenburg, Chief Innovation Officer of ProQR. LEIDEN, the Netherlands, April 10, 2018 (GLOBE …

… ProQR to Present its Ophthalmology Pipeline at ARVO, … in our ophthalmology pipeline at ARVO”, said Noreen R. Henig, Chief Medical Officer at ProQR. “These programs have many common elements with QR-110 …

… ProQR nominates Bart Filius, COO and CFO at Galapagos and … and Bart to the Supervisory Board at a pivotal point in ProQR’s advancement to become a fully integrated inherited … retinal disease company,” said Daniel A. de Boer, CEO at ProQR. “Theresa brings significant global commercial and …

… ProQR annonce des premiers résultats positifs pour l'essai de … CAMBRIDGE, Massachussets, 11 oct. 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq :PRQR), une entreprise dédiée … héréditaires dans son ensemble », a déclaré Stephen R. Russell, M.D., professeur Schrage d'ophtalmologie et des …

… ProQR Announces that QR-010 Meets the Primary Endpoint in a … LEIDEN, the Netherlands, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … results of PQ-010-002 will be presented today by Noreen R. Henig M.D. and John P. Clancy M.D. at the North American …

… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … to present new data from the InSight study in H2 2021. ProQR’s Presentation Presentation title:  Safety and efficacy … Congenital Amaurosis type 10 (LCA10) Presenter:  Stephen R. Russell, MD, Professor and Director of Vitreoretinal …